Market Signal Briefing

VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (HS) and the first Phase 3 program using the higher clinical response level of HS Clinical Response (HiSCR) 75 as primary endpoint at week 16Data was analyzed, as per protocol and in accordance with regulatory agency feedback, using a composite strategy as the primary analysis and a treatment policy strategy to test the robustness of the results: difference between the two methods relates to the statistical handling of intercurrent eventsIn the combined VELA program, patients treated with sonelokimab experienced a clinically meaningful and statistically significant improvement across all primary and key secondary endpoints using both pre-specified strategies (p<0.001)In VELA-1, sonelokimab achieved statistical significance for all primary and key secondary endpoints using both pre-specified strategies (HiSCR75, delta to placebo of 17%, p<0.001)In VELA-2, intercurrent events in the higher-than-expected placebo arm precluded the study from achieving statistical significance in the week 16 primary endpoint using the composite strategy (HiSCR75, delta to placebo of 9%, p=0.053)The pre-specified treatment policy strategy provides for the analysis of data irrespective of intercurrent events; using this analysis, a statistically significant HiSCR75 at week 16 in VELA-1 and VELA-2 was achieved with sonelokimab (35% and 36%, respectively) vs placebo (18% and 26%, respectively); clinically meaningful and statistically significant benefit was also observed for all key secondary endpoints (Table 2)Sonelokimab continued to show a favourable safety profile with no new safety signals detected, including an absence of key events of interest such as suicidal ideation and behavior VELA progresses to its pre-specified week 52 readout and the Company will now seek to confirm the path to registration in HS with the appropriate regulatory authorities Other clinical studies with sonelokimab, including the Phase 3 VELA-TEEN trial in adolescent HS, the Phase 3 IZAR program and the Phase 2 P-OLARIS trial in psoriatic arthritis (PsA), the Phase 2 LEDA trial in palmoplantar pustulosis (PPP), and the Phase 2 S-OLARIS trial in axial spondyloarthritis (axSpA), continue as planned and are expected to support a catalyst-rich roadmapThe Company will hold a webcast on Monday, September 29 at 2pm CET / 8am EDT (link below) ZUG, Switzerland, September 28, 2025 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced the week 16 results of the Phase 3 VELA-1 and VELA-2 trials of its registrational global program in patients with moderate-to-severe hidradenitis suppurativa (HS).

The VELA program used the higher clinical response level of HS Clinical Response (HiSCR) 75 as the primary endpoint, which defines a response as an at least 75% reduction in abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count. Key secondary endpoints included the percentage of participants achieving HiSCR50 and the percentage of patients achieving a Dermatology Quality of Life Index (DLQI) total score reduction of >4 (minimal clinically important difference), among participants with a baseline DLQI >4, as well as other scores that reflect the evolving needs of HS patients, treating physicians and regulators. These included the percentage of participants achieving at least a 55% reduction in the International HS Severity Scoring System (IHS4-55), the percentage of participants achieving at least a 3 point improvement from baseline in the worst pain Numerical Rating Scale (NRS) among participants with a baseline score of at least 3 points, and the change from baseline in the HS-specific Quality of Life score (HiSQOL). A total of 838 patients were enrolled across both trials. The trials were identical in design comparing a single 120mg dose of sonelokimab to placebo with HiSCR75 reading out at week 16. From week 16, all patients receive the 120mg dose of sonelokimab through to 48 weeks, with a last assessment at week 52, followed by an open-label extension for up to two years. The Phase 3 program used a protocol design consistent with the Phase 2 MIRA trial, which identified the optimal dose of sonelokimab for HS. The VELA protocols and statistical analysis plans were prepared in accordance with regulatory agency advice and include two analysis strategies. The composite strategy for the VELA trials is the primary statistical analysis. The protocol specifies the treatment policy strategy as the alternative method of handling intercurrent events to test the robustness of the VELA data. Data in this press release is presented using the aforementioned analysis strategies, as indicated throughout. The baseline characteristics for VELA-1 and VELA-2 are shown in Table 1.

TABLE 1

Baseline CharacteristicsTrials VELA 1VELA 2 Placebo
(n=138)SLK
(n=283)Placebo
(n=141)SLK
(n=276)Age [years], mean 36.137.238.037.2Female, % 62.361.549.653.6Race, % 
       White 
       Black or African American 76.1 
15.277.7 
12.085.1 
10.681.5 
9.4BMI, mean 33.633.532.733.0Current smoker, % 41.343.856.051.8Hurley Stage, % 
       II 
       III 63.8 
36.64.0 
36.067.4 
32.663.0 
37.0Years since diagnosis, mean 8.48.17.77.5Lesions, mean 
       AN count 
       DT count 13.3 
2.813.5 
3.213.8 
3.514.5 
3.9DLQI Total, mean 11.811.711.312.6HiSQOL Total, mean 27.626.523.828.0Patient Global Assessment of Skin Pain NRS, mean 4.94.75.04.9Prior biologic use, % 15.915.522.019.6Concomitant antibiotics, % 8.76.77.810.5 In the combined Phase 3 VELA program, all endpoints reached statistical significance with p-values below 0.001, including lesion counts and patient reported outcomes (PROs), as per Table 2. Sonelokimab demonstrated the expected profile of response over time, with statistically significant HiSCR75 for both studies achieved as early as week 4 (Table 3). A preliminary analysis suggests that responses continue to improve beyond week 16 and that placebo patients crossing over at week 16 achieve similar responses to those originally randomized to the sonelokimab 120mg arm, as of week 20 (pre-specified analysis, data not shown).

Using the treatment policy strategy as per protocol, both VELA-1 and VELA-2 showed a statistically significant increase in the percentage of participants achieving HiSCR75 at week 16 and provided a clinically meaningful benefit (Table 2). Response rates for sonelokimab 120mg were consistent between the two trials, with 34.8% and 35.9% of patients in VELA-1 and VELA-2 achieving HiSCR75 at week 16, respectively. The placebo response rate in VELA-1 of 17.5% at week 16 was within the historical Phase 3 range of 13% to 18%. The placebo response rate in VELA-2 of 25.6% at week 16 was higher than expected.

Both VELA-1 and VELA-2 achieved statistical significance for all key secondary endpoints (Table 2). This includes other lesion count based endpoints (HiSCR50 and IHS4-55). It also includes relevant PROs in HS. Around 30% of patients experienced a marked reduction of pain, as measured by an at least 3-point improvement in the worst pain NRS, in both VELA-1 and VELA-2 (p≤0.002). Sonelokimab showed a significant improvement of HiSQOL score at week 16 (p<0.001), which was consistent between VELA-1 and VELA-2. Almost 60% of patients achieved a meaningful (4 points or more) improvement of DLQI, an approximately 20 percentage-point benefit over placebo (p≤0.001).

Overall, the week 16 endpoint results using the treatment policy strategy were as follows:

TABLE 2

EndpointTrialClassTypeScoreVELA combinedVELA-1VELA-2Placebo (n=279)SLK 120mg (n=559)p-valuePlacebo (n=138)SLK 120mg (n=283)p-valuePlacebo (n=141)SLK 120mg (n=276)p-valuePrimaryLesion countHiSCR75 (%)21.635.4<0.00117.534.8<0.00125.635.90.033Key secondaryHiSCR50 (%)36.755.1<0.00130.351.6<0.00143.058.70.003IHS4-55 (%)39.455.7<0.00134.254.4<0.00144.756.90.021Patient-reported outcome (PRO)Pain NRS 3pt (%)13.929.1<0.00112.728.40.00114.929.80.002HiSQOL (CFB)-3.5-9.1<0.001-3.8-9.4<0.001-3.5-9.0<0.001DLQI (MCID, %)38.358.6<0.00137.859.0<0.00139.058.10.001 Note 1: ITT, pre-specified treatment policy strategy
Note 2: Across the VELA program all deltas to placebo vary between treatment policy and composite strategy by less than 1.5 percentage points (HiSQOL varies by less than 0.5 points)
Note 3: For VELA-1 and VELA-2, using composite strategy, all primary and key secondary endpoints achieved p<0.025 except for VELA-2 primary endpoint (HiSCR75, p=0.053); control for multiple testing was only performed within the composite strategy testing for VELA-1 and VELA-2 individually. Statistical significance refers to analyses where p<0.05, in both multiplicity and non-multiplicity controlled strategies
Note 4: “Pain NRS 3pt “ refers to Worst Pain NRS reduction of at least 3 points; “CFB” refers to mean change from baseline; “MCID” refers to minimally clinically important difference which reflects a reduction of at least 4 points in the score

The percentage of participants achieving HS Clinical Response (HiSCR) 75 at different timepoints was as follows:

TABLE 3

TrialArmTime (weeks)02481216VELA combinedPlacebo (n=279)06.17.117.117.821.6SLK 120mg (n=559)08.819.230.335.835.4Delta02.712.113.118.013.8p-value 0.157<0.001<0.001<0.001<0.001VELA-1Placebo (n=138)07.36.514.115.817.5SLK 120mg (n=283)08.920.529.533.834.8Delta01.614.015.418.017.3p-value 0.570<0.001<0.001<0.001<0.001VELA-2Placebo (n=141)05.07.620.119.825.6SLK 120mg (n=276)08.618.031.137.935.9Delta03.710.411.118.110.3p-value 0.1450.0020.011<0.0010.033 Note 1: ITT, pre-specified treatment policy strategy (time points other than week 16 were pre-specified Other secondary endpoints)
Note 2: Multiplicity control was only applied for testing of the primary and key secondary endpoints at week 16 by composite strategy in VELA-1 and VELA-2 individually. Statistical significance refers to analyses where p<0.05, in both multiplicity and non-multiplicity controlled strategies

The safety profile of sonelokimab was consistent with previously reported studies with no new safety signals observed. This includes the absence of new signals in key events of interest with IL-17A and F therapies: Suicidal Ideation and Behavior, hepatic events, IBD and non-infectious diarrhea, MACE and Eczema and Dermatitis (Table 4).

TABLE 4

Participants with event, n (%) Placebo(n=279)

 Sonelokimab 120 mg(n=559)

 Any TEAE 155 (55.6) 376 (67.3)       Any serious TEAE 5 (1.8) 14 (2.5)       Any TEAE leading to treatment discontinuation 4 (1.4) 16 (2.9)       Most frequent TEAEs1                  Nasopharyngitis 28 (10.0) 48 (8.6)              Headache 14 (5.0) 27 (4.8)              Upper respiratory tract infection 21 (7.5) 24 (4.3)       Safety topics of interest                  IBD2 0 0              Diarrhea (non-infectious)3 1 (0.4) 2 (0.4)              Oral candidiasis4 1 (0.4) 41 (7.3)              Serious hypersensitivity 0 0              Dermatitis & Eczema5 7 (2.5) 20 (3.6)              Serious infections 2(0.7) 4 (0.7)              SI/B6 0 0              Hepatic events7 3 (1.1) 1 (0.2)              MACE8 0 0  1 Most frequent TEAEs excluding safety topics of interest (as presented separately in this table) and one TEAEs to maintain blinding of the ongoing VELA studies 2 AESI, events in adjudication; 3 AESI; 4 there were three cases of oesophageal candida and two cases of oropharyngeal candida on SLK; 5 PTs eczema and dermatitis; 6 Reported adverse events, 7 Hepatic events (all hepatic AEs and laboratory investigations in adjudication to possible DILI); 8 Events in adjudication

Overall, the Company believes that sonelokimab continues to show a favorable safety profile, with no new safety signals detected and a competitive outlook. The VELA program is conducted using a convenient sub-cutaneous dosing scheme with 1ml volume delivered every other week to week 6 in the induction phase (4 injections), and monthly from week 8 for maintenance, with no up-titration. This profile is matched by improvements of HS lesions, including draining tunnels, as well as in all key Patient Reported Outcomes (PROs), such as quality-of-life and pain scores, that are meaningful for HS patients and their treating physicians.

   
Prof. Kristian Reich, Founder and Chief Scientific Officer at MoonLake, commented: “We are encouraged by the results of VELA-1, which follow the expected performance of sonelokimab in all the important metrics for patients and treating physicians. The higher-than-expected placebo response rate in VELA-2 is disappointing but we are encouraged by the consistent performance of sonelokimab arms across all endpoints in both studies. We are pleased to see a favorable safety profile consistent with previous studies, with no new safety signals. We believe that this, together with the convenient dosing, the efficacy data in the lesion-based metrics and the patient reported outcomes, shows the potential for a promising profile of sonelokimab in HS. Patients with HS are in desperate need of new treatment options and we remain committed to our path forward in HS.”

These interim results will now be discussed with the appropriate regulators, including the analytical strategies considering the higher-than-expected placebo response rate in VELA-2 at week 16 and path to submission of a Biologics License Application.

The Company continues to progress with the development of its Nanobody® sonelokimab across a portfolio of indications, including:

Q4 2025: Primary endpoint readout of the Phase 2 LEDA trial in PPPQ1 2026: Primary endpoint readout of the Phase 2 S-OLARIS trial in axSpAQ2 2026: 52 weeks data of the VELA-1 and VELA-2 trials in HSH1 2026: Primary endpoint readout of Phase 3 VELA-TEEN trial in adolescent HSH1 2026: Primary endpoint readout of Phase 3 IZAR program in PsA The Company will hold a webcast on Monday 29th of September at 2pm CET / 8am EDT. Link to the webcast, a replay of it and the presentation document will be made available at https://ir.moonlaketx.com.

Sonelokimab is not yet approved for use in any indication.

-Ends-

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody® for the treatment of inflammatory disease, to revolutionize outcomes for patients. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. The Company’s focus is on inflammatory diseases with a major unmet need, including hidradenitis suppurativa and psoriatic arthritis – conditions affecting millions of people worldwide with a large need for improved treatment options. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland. Further information is available at www.moonlaketx.com.

About Nanobodies®

Nanobodies® represent a new generation of antibody-derived targeted therapies. They consist of one or more domains based on the small antigen-binding variable regions of heavy-chain-only antibodies (VHH). Nanobodies® have a number of potential advantages over traditional antibodies, including their small size, enhanced tissue penetration, resistance to temperature changes, ease of manufacturing, and their ability to be designed into multivalent therapeutic molecules with bespoke target combinations.

The terms Nanobody® and Nanobodies® are trademarks of Ablynx, a Sanofi company.

About Sonelokimab

Sonelokimab (M1095) is an investigational ~40 kDa humanized Nanobody® consisting of three variable regions of heavy-chain-only antibodies domains (VHHs) covalently linked by flexible glycine-serine spacers. With two domains, sonelokimab selectively binds with high affinity to IL-17A and IL-17F, thereby inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers. A third central domain binds to human albumin, facilitating further enrichment of sonelokimab at sites of inflammatory edema.

Sonelokimab is being assessed in two lead indications, hidradenitis suppurative (HS) and psoriatic arthritis (PsA), and the Company is pursuing other indications in dermatology and rheumatology, including adolescent HS, palmo-plantar pustulosis (PPP) and axial spondyloarthritis (axSpA).

For adults with HS, sonelokimab is being assessed in the Phase 3 trials, VELA-1 and VELA-2, following the successful outcome of MoonLake’s end-of-Phase 2 interactions with the FDA and as well as positive feedback from its interactions with the EMA announced in February 2024. In June 2023, topline results of the MIRA trial (NCT05322473) at 12 weeks showed that the trial met its primary endpoint, the Hidradenitis Suppurativa Clinical Response (HiSCR) 75, which is a higher measure of clinical response versus the HiSCR50 measure used in other clinical trials, setting a landmark milestone. In October 2023, the full dataset from the MIRA trial at 24 weeks showed that maintenance treatment with sonelokimab led to further improvements in HiSCR75 response rates and other high threshold clinical and patient relevant outcomes. The safety profile of sonelokimab in the MIRA trial was consistent with previous trials with no new safety signals detected.

Sonelokimab is currently undergoing evaluation in the VELA-TEEN Phase 3 trial, which is the first clinical study specifically focused on adolescent patients with moderate-to-severe HS.

For PsA, sonelokimab is being assessed in the Phase 3 trials, IZAR-1 and IZAR-2, following the announcement in March 2024 of the full dataset from the global Phase 2 ARGO trial (M1095-PSA-201) evaluating the efficacy and safety of the Nanobody® sonelokimab over 24 weeks in patients with active PsA. Significant improvements were observed across all key outcomes, including approximately 60% of patients treated with sonelokimab achieving an American College of Rheumatology (ACR) 50 response and Minimal Disease Activity (MDA) at week 24. This followed the positive top-line results in November 2023, where the trial met its primary endpoint with a statistically significant greater proportion of patients treated with either sonelokimab 60mg or 120mg (with induction) achieving an ACR50 response compared to those on placebo at week 12. All key secondary endpoints in the trial were met for the 60mg and 120mg doses with induction. The safety profile of sonelokimab in the ARGO trial was consistent with previous trials with no new safety signals detected.

Sonelokimab is also being assessed in the Phase 2 LEDA trial, which is ongoing for PPP, a debilitating inflammatory skin condition affecting a significant number of patients.

Additionally, Sonelokimab is being assessed in the ongoing Phase 2 S-OLARIS trial for active axSpA. The trial features an innovative design complementing traditional clinical outcomes with cellular imaging techniques.

Sonelokimab has also been assessed in a randomized, placebo-controlled third-party Phase 2b trial (NCT03384745) in 313 patients with moderate-to-severe plaque-type psoriasis. High threshold clinical responses (Investigator’s Global Assessment Score 0 or 1, and Psoriasis Area and Severity Index 90/100) were observed in patients with moderate-to-severe plaque-type psoriasis. Sonelokimab was generally well tolerated, with a safety profile similar to the active control, secukinumab (Papp KA, et al. Lancet. 2021; 397:1564-1575).

In an earlier third-party Phase 1 trial in patients with moderate-to-severe plaque-type psoriasis, sonelokimab has been shown to decrease (to normal skin levels) the cutaneous gene expression of pro-inflammatory cytokines and chemokines (Svecova D. J Am Acad Dermatol. 2019;81:196–203).

About the VELA program

The Phase 3 VELA program has enrolled over 800 patients across VELA-1 and VELA-2. Both global, randomized, double-blind, placebo-controlled trials are identical in design evaluating the efficacy and safety of the Nanobody® sonelokimab, administered subcutaneously, in adult patients with active moderate-to-severe hidradenitis suppurativa. Similar to the design of the landmark Phase 2 MIRA trial, the primary endpoint is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75, defined as a ≥75% reduction in total abscess and inflammatory nodule (AN) count with no increase in abscess or draining tunnel count relative to baseline. The trials will also evaluate a number of secondary endpoints, including the proportion of patients achieving HiSCR50, the change from baseline in International Hidradenitis Suppurativa Severity Score System (IHS4), the proportion of patients achieving a Dermatology Life Quality Index (DLQI) total reduction of ≥4, the proportion of patients achieving at least 50% reduction from baseline in Numerical Rating Scale (NRS50) in the Patient’s Global Assessment of Skin Pain (PGA Skin Pain) and complete resolution of Draining Tunnels (DT100). The VELA protocols and statistical analysis plans were prepared in accordance with regulatory agency advice and include two analysis strategies. The composite strategy for the VELA trials (also referred to as the primary estimand) is the primary statistical analysis. The protocol specifies the treatment policy strategy as the alternative method of handling intercurrent events to test the robustness of the VELA data. Data in this press release is presented using the aforementioned analysis strategies, as indicated throughout. Further details are available under NCT06411379 and NCT06411899 at ClinicalTrials.gov.

About the VELA-TEEN trial

The Phase 3 VELA-TEEN trial is an open-label, single-arm trial designed to evaluate sonelokimab 120mg administered subcutaneously once every two weeks (Q2W) until week six and once every four weeks (Q4W) from week eight onwards. The trial aims to enroll 30-40 adolescents, aged 12-17, with moderate-to-severe hidradenitis suppurativa, from U.S. sites experienced in clinical trials and pediatric dermatology. The primary trial phase will be 24 weeks with a primary endpoint evaluating the pharmacokinetics, safety, and tolerability of sonelokimab. VELA-TEEN will also evaluate several secondary endpoints, including the proportion of patients achieving the higher clinical response measure of the Hidradenitis Suppurativa Clinical Response Score (HiSCR) 75, in addition to HiSCR50. Other outcomes are the change from baseline in the International Hidradenitis Suppurativa Severity Score System (IHS4), which includes the quantitative measure of draining tunnels, and the proportion of patients achieving a meaningful reduction of the Children’s Dermatology Life Quality Index (CDLQI) and the Patients Global Assessment of Skin Pain (PGA Skin Pain). Further details are available under NCT06768671 at ClinicalTrials.gov.

About Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a severely debilitating chronic skin condition resulting in irreversible tissue destruction. HS manifests as painful inflammatory skin lesions, typically around the armpits, groin, and buttocks. Over time, uncontrolled and inadequately treated inflammation can result in irreversible tissue destruction and scarring. The disease affects an estimated 2% of the population, with three times more females affected than males. Real-world data in the US indicates that at least 2 million unique patients have been diagnosed with and treated for HS between 2016 and 2023 alone, highlighting a significant unmet need and impact on healthcare systems, and a market opportunity projected to reach $15bn by 2035. Onset typically occurs in early adulthood and HS has a profound negative impact on quality of life, with a higher morbidity than other dermatologic conditions. There is increasing scientific evidence to support IL-17A- and IL-17F-mediated inflammation as a key driver of the pathogenesis of HS, with other identified risk factors including genetics, cigarette smoking, and obesity.

About the IZAR Program

IZAR-1 (NCT06641076) and IZAR-2 (NCT06641089) are global, randomized, double-blind, placebo-controlled Phase 3 trials designed to evaluate the efficacy and safety of sonelokimab compared with placebo in a total of approximately 1,500 adults with active psoriatic arthritis (PsA), with a primary endpoint of superiority to placebo in American College of Rheumatology (ACR) 50 response at Week 16. IZAR-1 is expected to enroll biologic-naïve patients and include an evaluation of radiographic progression, while IZAR-2 is expected to enroll patients with an inadequate response to tumor necrosis factor-α inhibitors (TNF-IR) — reflecting patients commonly seen in clinical practice — and is the first PsA trial to include a risankizumab active reference arm. Both trials will also assess a range of secondary endpoints reflecting the multiple disease manifestations characteristic of PsA. These include skin and nail outcomes, multidomain outcomes, and patient-reported outcome measures such as pain and quality of life assessments. Further details are available under NCT06641076 and NCT06641089 at ClinicalTrials.gov.

About Psoriatic Arthritis

Psoriatic arthritis (PsA) is a chronic, progressive and complex inflammatory disease that manifests across multiple domains, leading to substantial functional impairment and decreased quality of life. The clinical features of PsA are diverse, comprising both musculoskeletal (peripheral arthritis, spondylitis, dactylitis, and enthesitis) and non-musculoskeletal (skin and nail disease) domains. PsA occurs in up to 30% of patients with psoriasis, most commonly those aged between 30 and 60 years. Although the exact mechanism of disease is not fully understood, evidence suggests that activation of the IL-17 pathway plays an important role in the disease pathophysiology.

About the S-OLARIS trial

S-OLARIS is an open-label Phase 2 proof-of-concept trial aiming to investigate sonelokimab 60mg administered subcutaneously in approximately 25 patients with active axial spondylarthritis (axSpA). The primary endpoint is the change from baseline (CfB) at week 12 in the uptake of 18F-NaF in the sacroiliac joints and spine using PET in combination with MRI imaging. Throughout the trial, several other endpoints will be assessed including established clinical disease activity outcomes (e.g., ASAS), scores related to physical function, spinal mobility, and enthesitis as well as patient reported outcomes. The trial also includes an exploratory peripheral blood and tissue biomarker program.

About Axial Spondyloarthritis

Axial Spondyloarthritis (axSpA) typically impacts young people, with diagnosis based on chronic inflammatory back pain lasting more than three months with onset under 45 years of age. Advanced disease can lead to progressive and pathologic bone formation and joint fusion, severely limiting spinal mobility. Global reported prevalence of axSpA ranges from 0.5% to 1.5%. AxSpA can be categorized by disease progression into two subtypes: non-radiographic axSpA and ankylosing spondylitis (AS), also known as radiographic axSpA, which is diagnosed based on radiographic evidence of structural changes to the sacroiliac joints. Patients with axSpA experience fatigue, persistent morning stiffness, and pain that worsens at night and can disrupt sleep. Many patients also face the burden of comorbidities such as psoriatic arthritis and psoriasis. Studies have found elevated IL-17 levels in the blood and synovial fluid of patients with axSpA, and IL-17A and IL-17F are both thought to be key contributors to pathogenesis across the spondyloarthropathies.

About the LEDA Trial

The LEDA trial is a Phase 2 trial designed to evaluate the efficacy and safety of sonelokimab 120mg administered subcutaneously in adult patients with palmoplantar pustulosis (PPP). The primary endpoint of the trial is percent change from baseline in Palmoplantar Psoriasis Area and Severity Index (ppPASI) with important secondary endpoints including ppPASI75 (at least 75% improvement in the ppPASI). The LEDA trial features an innovative translational research program using peripheral blood and tissue biomarkers as trial controls.

The trial design has been informed by previous successful studies of sonelokimab, including the landmark Phase 2 MIRA trial in hidradenitis suppurativa, which identified the optimal dosing and demonstrated the potential of sonelokimab to target deep tissue inflammation effectively.

About Palmoplantar Pustulosis

Palmoplantar Pustulosis (PPP) is characterized by the development of blister-like pustules within erythematous, scaly plaques on the palms and the soles of the feet. PPP typically develops in adulthood, more frequently impacts females. Patients frequently experience significant pain, burning, and itching sensations on the palms and soles of the feet which can be debilitating and impair their ability to work, sleep, or perform other activities of daily living. Currently, the treatment of PPP is challenging with a significant unmet need for novel therapies to reduce the symptom burden for patients. Evidence suggests that activation of the IL-17 pathway has an important role in disease pathophysiology.

Cautionary Statement Regarding Forward Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding MoonLake’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: trial design, plans for and timing of clinical trials; whether the regulatory agencies agree that the two statistical strategies, when reviewed together, provide substantial evidence of efficacy in the VELA program, recognizing that under the composite strategy, VELA-2 failed to show a statistically significant improvement over placebo at week 16 on the primary endpoint; enrollment for clinical trials, including the VELA-TEEN trial and the IZAR program; the efficacy and safety of sonelokimab for the treatment of adult HS, adolescent HS, PPP, PsA and axSpA, including in comparison to existing standards or care or other competing therapies, clinical trials and research and development programs; the anticipated timing of the results from those studies and trials, and potential market opportunities for sonelokimab and MoonLake’s anticipated cash position. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.

Forward-looking statements are based on current expectations and assumptions that, while considered reasonable by MoonLake and its management, as the case may be, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that interim data in the VELA trials are not consistent with the final 52-week data, risks and uncertainties associated with MoonLake’s business in general and limited operating history, difficulty enrolling patients in clinical trials, state and federal healthcare reform measures that could result in reduced demand for MoonLake’s product candidates and reliance on third parties to conduct and support its preclinical studies and clinical trials and the other risks described in or incorporated by reference into MoonLake’s most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission.

Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. MoonLake does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or in the events, conditions or circumstances on which any such statement is based.

Contacts:

MoonLake Immunotherapeutics Media & Investors Relations

Carla Bretes, Director IR & External Communications

[email protected]

ICR Healthcare

Mary-Jane Elliott, Namrata Taak, Ashley Tapp

Tel: +44 (0) 20 3709 5700

[email protected]

If you are looking for a source of income that outlives you, look into dividend ETFs that are time-tested over decades.

, /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fortinet, Inc. (NASDAQ: FTNT) common stock between November 8, 2024 and August 6, 2025, both dates inclusive (the "Class Period"), have until November 21, 2025 to seek appointment as lead plaintiff of the Fortinet class action lawsuit.  Captioned Oklahoma Firefighters Pension and Retirement System v. Fortinet, Inc., No. 25-cv-08037 (N.D. Cal.), the Fortinet class action lawsuit charges Fortinet as well as certain of Fortinet's top current and former executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Fortinet class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-fortinet-inc-class-action-lawsuit-ftnt.html  

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected].

CASE ALLEGATIONS: Fortinet provides cybersecurity and convergence of networking and security solutions.

The Fortinet class action lawsuit alleges that: (i) defendants knew that the refresh cycle would never be as lucrative as they represented, nor could it, because it consisted of old products that were a "small percentage" of Fortinet's business; (ii) defendants misrepresented and concealed that they did not have a clear picture of the true number of FortiGate firewalls that could be upgraded; and (iii) while telling investors that the refresh would gain momentum over the course of two years, Fortinet misrepresented and concealed that it had aggressively pushed through roughly half of the refresh in a period of months, by the end of the second quarter of 2025.

The Fortinet class action lawsuit further alleges that on August 6, 2025, Fortinet revealed during its earnings call that Fortinet was already "approximately 40% to 50% of the way through the 2026 upgrade cycle at the end of the second quarter [of 2025]."  The complaint also alleges that defendants: (i) admitted that "it's hard[] for us to predict" the total number of FortiGates requiring an upgrade; (ii) suggested customers had "excess [firewall] capacity from [purchasing firewalls in] prior years" and therefore did not need to upgrade; and (iii) revealed that the refresh could not have had "much business impact" as it consisted of only a "small percentage" of Fortinet's business because the products were "12 to 15 years" old and had been sold at a time when Fortinet's business was 5-10 times smaller, meaning that the total number of FortiGates eligible for an upgrade was inherently limited.  On this news, the price of Fortinet common stock fell more than 22%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Fortinet common stock during the Class Period to seek appointment as lead plaintiff in the Fortinet class action lawsuit.  A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.  A lead plaintiff acts on behalf of all other class members in directing the Fortinet class action lawsuit.  The lead plaintiff can select a law firm of its choice to litigate the Fortinet class action lawsuit.  An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Fortinet class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation.  Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors.  In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS.  With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.  Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 

Services may be performed by attorneys in any of our offices. 

Contact:

            Robbins Geller Rudman & Dowd LLP

            J.C. Sanchez, Jennifer N. Caringal

            655 W. Broadway, Suite 1900, San Diego, CA 92101

            800-449-4900

            [email protected] 

SOURCE Robbins Geller Rudman & Dowd LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

NEW YORK, Sept. 28, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of V.F. Corporation (NYSE: VFC) between October 30, 2023 and May 20, 2025, both dates inclusive (the “Class Period”), of the important November 12, 2025 lead plaintiff deadline.

SO WHAT: If you purchased V.F. Corporation securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the V.F. Corporation class action, go to https://rosenlegal.com/submit-form/?case_id=44811 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 12, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants disseminated materially false and misleading statements and/or concealed material adverse facts concerning the true state of V.F. Corporation’s turnaround plans. Specifically, defendants provided investors with material information concerning V.F. Corporation’s turnaround plan (“Reinvent”), which in part focused on efforts to return the Vans brand to positive growth. The lawsuit alleges that defendants concealed that additional significant reset actions would be necessary to return the Vans brand to growth, and would result in significant setbacks to Vans’ revenue growth trajectory. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the V.F. Corporation class action, go to https://rosenlegal.com/submit-form/?case_id=44811 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

SAN DIEGO, Sept. 28, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of KinderCare Learning Companies, Inc. (NYSE: KLC) common stock in or traceable to KinderCare’s October 2024 initial public offering (the “IPO”), have until Monday, October 13, 2025 to seek appointment as lead plaintiff of the KinderCare class action lawsuit. Captioned Gollapalli v. KinderCare Learning Companies, Inc., No. 25-cv-01424, and pending in the District of Oregon, the KinderCare class action lawsuit charges KinderCare as well as certain of KinderCare’s executives and directors, KinderCare’s controlling shareholder, and the underwriters of the IPO with violations of the Securities Act of 1933.

If you suffered substantial losses and wish to serve as lead plaintiff of the KinderCare class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-kindercare-learning-companies-inc-class-action-lawsuit-klc.html

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected].

CASE ALLEGATIONS: KinderCare provides early education and child care services in the United States. In the IPO, KinderCare sold over 27 million shares of common stock to investors at $24 per share, raising $648 million in gross offering proceeds.

The KinderCare class action lawsuit alleges that the registration statement for the IPO was false and/or misleading and/or failed to disclose that: (i) numerous incidents of child abuse, neglect, and harm had occurred at KinderCare facilities; (ii) KinderCare did not provide the “highest quality care possible” at its facilities, and, indeed, in numerous instances had failed to provide even basic care, meet minimum standards in the child care industry, or comply with the laws and regulations governing the care of children; and (iii) as a result, KinderCare was exposed to a material, undisclosed risk of lawsuits, adverse regulatory action, negative publicity, reputational damage, and business loss.

Since the IPO, the price of KinderCare stock fell to lows near $9 per share.

The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased KinderCare common stock in or traceable to the IPO to seek appointment as lead plaintiff in the KinderCare class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the KinderCare class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the KinderCare class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the KinderCare class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        J.C. Sanchez, Jennifer N. Caringal
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800-449-4900
        [email protected]

NEW YORK, Sept. 28, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Lineage, Inc. (NASDAQ: LINE) common stock pursuant and/or traceable to the registration statement issued in connection with Lineage’s July 2024 initial public offering (the “IPO”) of the important September 30, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Lineage common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Lineage class action, go to https://rosenlegal.com/submit-form/?case_id=43296 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 30, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the registration statement was false and/or misleading and/or failed to disclose that: (1) Lineage was then experiencing sustained weakening in customer demand, as additional cold-storage supply had come on line, Lineage’s customers destocked a glut of excessive inventory built up during the COVID-19 pandemic, and Lineage’s customers shifted to maintaining leaner cold-storage inventories on a go-forward basis in response to changed consumer trends; (2) Lineage had implemented price increases in the lead-up to the IPO that could not be sustained in light of the weakening demand environment facing Lineage; (3) Lineage was unable to effectively counteract the adverse trends listed above through the use of minimum storage guarantees or as a result of operational efficiencies, technological improvements, or its purported competitive advantages; (4) as a result, rather than enjoying stable revenue growth, high occupancy rates, and steady rent escalation as represented in the registration statement, Lineage was in fact suffering from stagnant or falling revenue, occupancy rates, and rent prices; and (5) consequently, Lineage’s financial results, business operations, and prospects were materially impaired. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Lineage class action, go to https://rosenlegal.com/submit-form/?case_id=43296 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Pfizer is facing a patent cliff and has a high payout ratio, but it is taking steps to get back on track.

Pfizer (PFE 0.64%) has a huge 7.1% dividend yield. That certainly compares favorably to the broader market's 1.2% yield and the average healthcare stock's yield of 1.7%. But Pfizer's lofty yield only exists because of a worrying 55% stock price decline since late 2022.

That kind of price decline doesn't happen by accident, which means you need to carefully consider whether this high-yield stock is worth adding to your income portfolio. Let's dig in and try to find out.

Image source: Getty Images.

What does Pfizer do?
Pfizer is one of the largest pharmaceutical companies in the world. It has a very long and successful history of finding, developing, and selling drugs, including dealing with the very difficult task of getting promising drugs approved for human use. It competes well with other drug makers and it is highly unlikely that the business is going to go away anytime soon.

That said, the stock has fallen a shocking 55% since late 2022. Even well-run businesses go through hard times and, pretty clearly, this is a hard time for Pfizer. There are two broad issues to consider.

First, there's been a shift in the view of drug makers, driven by reduced trust among consumers since the COVID-19 pandemic. That has been particularly troubling for Pfizer, which happens to make vaccines, which are an increasingly contentious issue in the public sphere.

The mood shift has come against another important trend for Pfizer, but one that is fairly normal in the pharma space. Drug companies are granted temporary exclusivity on new drugs because of the cost of drug development. When those drugs lose their patent protections generic alternatives can be produced, usually leading to a material drop in revenue for the original drug.

This is called a patent cliff in the industry and Pfizer is nearing just such a cliff starting in 2027, when oncology drug Ibrance comes off patent. That will be followed in 2028 with cardiovascular drugs Eliquis and Vyndaqel losing patent protections in 2028.

PFE data by YCharts

Pfizer is doing what needs to be done
Pfizer can't do much about the negative view of vaccines other than wait for the mood to shift. It likely will, given the long history of vaccines improving health outcomes. But the company can do something about patent cliffs, which basically require the healthcare giant to invest in new drugs.

One way it does this is with internal research and development. The problem is that R&D is an inherently lumpy process, so success isn't guaranteed and isn't likely to unfold on a set time frame that coincides with the company's patent expirations. A recent high profile failure came in the obesity drug arena.

But there's another option. Pfizer is large enough to simply go out and buy other companies with promising drugs. It did just that recently when it agreed to buy Metsera (MTSR -0.49%). The agreement calls for an upfront payment of $47.50 per share for Metsera, or about $4.9 billion in total. However, there are three contingent payments that could add up to $22.50 per share to the deal, increasing the overall cost by billions of dollars.

The key goal of the transaction is to get access to Metsera's promising drug pipelines, including in the obesity space. This is good news for Pfizer's business and management is, basically, doing what it needs to do to ensure the company's long-term success.

Before you run out and buy high yield Pfizer, however, consider two more facts. Pfizer's trailing 12-month dividend payout ratio is a lofty 90%, which suggests that the dividend may not be as secure as some investors might like. And the board of directors chose to cut the dividend in 2009 following Pfizer's acquisition of Wyeth Pharmaceuticals.

The $68 billion Wyeth deal was a larger transaction, but with such a high dividend payout ratio, the risk of a dividend cut following a material acquisition shouldn't be ignored. Also important to consider here is the fact that the drug candidates Pfizer is acquiring aren't guaranteed to be blockbuster drugs, which is why an earnout model was used in determining the price of the deal.

Buy the business, not the dividend
Given the steep price decline, there is turnaround appeal in Pfizer's stock today. And notably, management and the board are doing what is necessary to get the company back on track, namely investing (internally and via acquisition) in new drugs. It is highly likely that Pfizer does, eventually, get back on the growth track.

But the lofty payout ratio and a history of cutting the dividend suggests that income seekers should probably tread with caution. This pharma giant may not be as safe a dividend stock as you want it to be.

Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.

If you are looking for reliable businesses to add to your portfolio while the market flirts with all-time highs, these dividend payers need to be on your short list.

The S&P 500 (SNPINDEX: ^GSPC) index is hovering around its all-time highs, and stretched valuations are making buying stocks a bit more worrisome right now. Don't fret: Whether you have $1,000 or $100,000 that you're ready to invest, you have options. Three strong possibilities to buy right now are integrated energy giant Chevron (CVX -0.37%), utility giant NextEra Energy (NEE 1.59%), and beverage giant Coca-Cola (KO -0.52%). Here's a look at each of these reliable dividend stocks.

1. Chevron is built to survive hard times
Chevron's business is diversified across the energy landscape, with assets in the energy production, energy transportation, and chemicals and refining segments. Each of these parts of the energy sector performs a bit differently through the phases of the energy cycle, so having exposure to all of them helps cushion Chevron against the impacts of soaring or slumping commodity prices.

On top of that, Chevron happens to have one of the strongest balance sheets among its close peers, with a debt-to-equity ratio of 0.2. During energy sector downturns, when its earnings slide, Chevron has the flexibility to take on debt to support its business and dividend. When energy prices recover, as they always have historically, it can (and does) pay those debt levels down again.

Its combination of a diversified business model and a strong financial foundation has allowed Chevron to increase its dividend annually for 38 consecutive years. That's an incredible streak given the inherent volatility of the energy sector. At the current share price, its dividend yield is about 4% -- well above average for the broader market and the energy industry specifically. So if you're in search of a reliable high-yield stock, you might want to put Chevron on your short list. A $1,000 investment would buy you about six shares of the stock.

Image source: Getty Images.

2. NextEra Energy is a dividend growth machine
NextEra Energy is really two businesses in one. First, the company operates regulated utilities, largely in Florida. The Sunshine State has long benefited from in-migration, and a growing base of customers means more revenues for NextEra and an easier time getting rate hikes and capital investment approved by government regulators. On top of that, NextEra has built one of the world's largest solar and wind power businesses. This is its major growth driver -- the company expects to roughly double its clean energy capacity over the next few years.

The key factor that attracts investors to NextEra stock, however, is its dividend. At the current share price, its dividend yield is around 3.1%, which is above the 2.7% average for a utility. And, on top of that, NextEra has grown its payouts at an annualized clip of 10% a year over the last decade. That would be a really good clip for just about any company, but for a utility, it's even more impressive. And based on management's forecasts, it will keep that pace up through at least 2026.

If you like dividend growth stocks, this relatively boring utility could be right up your alley. An investment of $1,000 would buy you roughly 13 shares.

3. Coca-Cola is fairly priced
Coca-Cola is the least attractive of this trio from a dividend yield perspective, given that it "only" pays 3% or so at its current share price. That yield, however, is well above the 1.2% average of the S&P 500 index and tops the consumer staples sector's average of about 2.5%. The big draw here is that Coca-Cola is a Dividend King -- one of the rare companies with dividend-hiking streaks of 50 straight years or more. Coca-Cola's streak, in fact, has run for 64 years.

It's also one of the best-known companies on the planet, selling an array of beverages from its namesake cola and other soft drinks to juices, energy drinks, coffee, and tea. Right now, consumers generally seem to be growing more interested in eating healthy, which has Wall Street a bit worried about the soda maker's future. That helps explain why a stock sell-off has pushed its price-to-sales and price-to-earnings ratios below their five-year averages.

Coca-Cola, though, has navigated through hard times before and will likely be able to do so again. So with the stock trading at a reasonable valuation, there's an opportunity here for new investors. 

If you like to own the most reliable dividend stocks, Coca-Cola should be on your watch list, if not your buy list, right now. A $1,000 investment will buy you around 15 shares.

Plenty of options even in an expensive market
It would be understandable for investors to think that with the S&P 500 at such a lofty level, there are no good deals on stocks to be found right now. Yet Chevron, NextEra Energy, and Coca-Cola show that's not the case. 

They are three of the best dividend choices out there today, but there are other similarly appealing options available if you look for them. Just make sure you take both the risks and the potential rewards into consideration whenever you examine a business. Each member of this trio has proven it has what it takes to survive the economy's rough patches and keep paying shareholders well all along the way.

Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Chevron and NextEra Energy. The Motley Fool has a disclosure policy.

September 28, 2025 11:15 ET

 | Source:

BridgeBio Pharma, Inc.

- By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo

- Acoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through Month 30 versus placebo with a 49% hazard reduction (p<0.0001)

- The difference in cumulative events increased progressively with results at Month 30 showing 53 events were avoided per 100 treated participants (95% CI:29–79)

PALO ALTO, Calif., Sept. 28, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, presented data from the ATTRibute-CM study showing that acoramidis reduced cumulative cardiovascular outcomes, including cardiovascular mortality (CVM) or recurrent cardiovascular-related hospitalizations (CVH), within the first month of treatment in patients with ATTR-CM. These data were presented in a Late Breaking Clinical Trials Oral Presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2025 and simultaneously published in Journal of the American College of Cardiology. Acoramidis is a selective, small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.

“Acoramidis demonstrated early and sustained clinical efficacy on the totality of cumulative cardiovascular outcomes, where accrued events start to numerically diverge within the first month of treatment,” said Ahmad Masri, M.D., M.S. of Oregon Health & Science University. “As a practicing cardiologist, these findings are incredibly meaningful because it draws attention to the time-sensitive nature of transthyretin amyloidosis diagnosis and treatment initiation, where a safe and effective treatment such as acoramidis can potentially have an early effect on reducing patients' risk of cardiovascular hospitalizations and events.”

Details from the late breaking oral presentation, Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis from ATTRibute-CM, presented by Dr. Masri included:

At Month 1, numerically fewer cumulative events were observed with acoramidis compared to placeboAcoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through Month 30 versus placebo with a 49% hazard reduction (p<0.0001)The difference in cumulative events increased progressively with results at Month 30 showing 53 events were avoided per 100 treated participants (95% CI:29–79)In addition to the late breaking oral presentation, a simultaneous publication in Journal of the American College of Cardiology, with the same title as the presentation, noted the same details and also concluded that at Month 42, CVM was reduced with continuous acoramidis versus placebo-to-acoramidis with a hazard reduction of 45% (p=0.0011) In addition to the late breaking oral presentation and simultaneous publication of the cumulative cardiovascular outcomes data from ATTRibute-CM, one oral presentation and three poster sessions were shared on the open-label extension data from ATTRibute-CM and real-world evidence. These findings included:

Continuous Acoramidis Treatment Significantly Reduced Risk of All-cause Mortality and Cardiovascular-related Hospitalization at Month 42, in Patients with Wild-type And Variant Transthyretin Amyloidosis Cardiomyopathy, shared in an oral presentation by Lily Stern, M.D. of Cedars-Sinai Heart Institute At Month 42, continuous acoramidis was associated with lower risk of all-cause mortality (ACM), first CVH, and ACM/first CVH vs placebo to acoramidis switch in both wild-type ATTR-CM and variant ATTR-CM, highlighting the importance of early and continuous acoramidis regardless of TTR genotype Acoramidis Mitigates the Rise in NT-proBNP Levels Observed with Placebo in Patients with Variant Transthyretin Amyloid Cardiomyopathy: Results from ATTRibute-CM, presented in a poster session by Nitasha Sarswat, M.D. of UChicago Medicine In the variant ATTR-CM subpopulation from ATTRibute-CM, acoramidis consistently mitigated the rise in N-terminal pro-B-type natriuretic peptide (NT-proBNP) observed in the placebo variant group, with effects starting at Month 3, and continuing through Month 30. Considering the higher risk posed by variant ATTR-CM, these findings are especially relevant in addressing the distinct medical needs of the variant ATTR-CM patient population Effect of Acoramidis on Cardiac Conduction Abnormalities in Transthyretin Amyloid Cardiomyopathy, presented in a poster session by Brett W. Sperry, M.D. of Saint Luke's Health System In ATTRibute-CM, acoramidis treatment was associated with numerically lower percentages of participants with worsening, prolonged PR or QRS intervals at Month 24 and Month 30, compared with placebo. These observations are consistent with the slowing of ATTR-CM disease progression previously reported with acoramidis State-Level Differences in Incidence of Transthyretin Amyloid Cardiomyopathy in United States Veterans Persist After Introduction of Disease-Modifying Therapy, presented in a poster session by Sandesh Dev, M.D. of Arizona State University The incidence of ATTR-CM in the U.S. Veteran population increased nationally in the setting of available treatment, possibly due to improved awareness in most states Acoramidis is approved as Attruby® by the U.S. FDA and is approved as BEYONTTRA® by the European Commission, Japanese Pharmaceuticals and Medical Devices Agency, and the UK Medicines and Healthcare Products Regulatory Agency with all labels specifying near-complete stabilization of TTR.

More data on the benefit of Attruby for ATTR-CM patients is planned for future medical meetings.

About Attruby™ (acoramidis)
INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

About BridgeBio
BridgeBio Pharma (BridgeBio; NASDAQ:BBIO) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible.  For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, Instagram, and YouTube.

BridgeBio Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “projects,” “potential,” “seeks,” “should,” “will,” and variations of such words or similar expressions. BridgeBio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements, including statements regarding the potential of acoramidis to have an early effect on reducing patients’ risk of cardiovascular hospitalizations and events, the timing of future data disclosures, and BridgeBio’s ongoing development pipeline, reflect BridgeBio’s current views about its plans, intentions, expectations, and strategies, which are based on the information currently available to BridgeBio and on assumptions it has made. Although BridgeBio believes that its plans, intentions, expectations, and strategies as reflected in or suggested by these forward-looking statements are reasonable, it can give no assurance that such plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties, and assumptions, including, but not limited to: the risks associated with BridgeBio’s dependence on third parties for development; regulatory authorities requiring additional studies or data to support the continued or expanded commercialization of acoramidis; whether data and results meet regulatory requirements or are sufficient for continued development, review, or approval; and whether other regulatory agencies agree with BridgeBio’s strategies or data interpretations. These risks also include impacts from global health emergencies, such as delays in regulatory reviews and other activities, manufacturing and supply chain interruptions, adverse effects on healthcare systems, and disruption of the global economy; and the impacts of macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and in Israel and the Gaza Strip, increasing inflation rates, and fluctuating interest rates on BridgeBio’s operations and expectations. Additional risks are described in the Risk Factors section of BridgeBio’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other filings with the U.S. Securities and Exchange Commission. Moreover, BridgeBio operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of BridgeBio’s management as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in these statements. Except as required by applicable law, BridgeBio assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
[email protected]  
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
[email protected]

Forget consumer chatbots -- IBM is targeting a much more lucrative AI market. Here's the overlooked opportunity that could drive massive growth for Big Blue's AI business.

With other tech giants sparring over consumer chatbots, IBM (IBM 1.22%) is quietly positioning itself to dominate a different artificial intelligence (AI) battlefield: the enterprise segment.

The centennial tech titan might seem like an unlikely AI winner, but there's one key factor that could make IBM the surprise star of the artificial intelligence revolution. IBM's AI solutions are tailor-made for large corporations.

Image source: Getty Images.

IBM's secret weapon: Enterprise-class AI
The watsonx platform for generative AI services isn't trying to write your poetry or plan your vacation. Instead, it's helping Fortune 500 companies deploy AI with strict attention to data security and regulatory requirements. Combined with Red Hat's OpenShift platform -- IBM's $34 billion acquisition from 2019 that's now paying proverbial dividends -- the company offers something unique: AI that works within existing enterprise infrastructure.

This isn't just theory. Banks are using IBM's watsonx to detect fraud while maintaining compliance with financial regulations. Healthcare systems are deploying IBM's AI to analyze patient data without violating patient privacy regulations.

It's all done with auditable data flows. Sure, watsonx will hallucinate from time to time, like any other system based on large language models (LLMs). But when it does, you'll be able to trace the error back to its original inspiration.

Meanwhile, IBM's consulting arm helps these enterprises make use of AI solutions. This unique focus on support services creates sticky, long-term business relationships.

The big blue numbers tell the story
IBM's AI-based Automation segment grew 14% year over year in Q2 2025, while Red Hat revenue continues its double-digit revenue expansion. The enterprise AI market is projected to reach $600 billion by 2028, and IBM is uniquely positioned to capture this opportunity.

Unlike consumer AI companies burning cash on compute costs, IBM's enterprise focus means higher margins and predictable revenue streams. While others chase the next viral chatbot, IBM is selling the picks and shovels of the enterprise AI gold rush -- and that's exactly why it will thrive. Buying IBM stock today should set you up for robust AI-boom gains.

Anders Bylund has positions in International Business Machines. The Motley Fool has positions in and recommends International Business Machines. The Motley Fool has a disclosure policy.

NEW YORK, Sept. 28, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Snap Inc. (NYSE: SNAP) between April 29, 2025 and August 5, 2025, both dates inclusive (the “Class Period”), both dates inclusive, of the important October 20, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Snap securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Snap class action, go to https://rosenlegal.com/submit-form/?case_id=2663 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 20, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period created the false impression that they possessed reliable information pertaining to Snap’s expected advertising revenue and anticipated growth while emphasizing potential macroeconomic instability. In truth, Snap’s optimistic reports of advertising growth and earnings potential fell short of reality as they relied far too heavily on Snap’s ability to execute on its potential; Snap was already experiencing the ramifications of a significant execution error when defendants’ claimed a lack of visibility due to macroeconomic conditions. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Snap class action, go to https://rosenlegal.com/submit-form/?case_id=2663 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

NEW YORK, Sept. 28, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PubMatic, Inc. (NASDAQ: PUBM) between February 27, 2025 and August 11, 2025, both dates inclusive (the “Class Period”), of the important October 20, 2025 lead plaintiff deadline.

SO WHAT: If you purchased PubMatic securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the PubMatic class action, go to https://rosenlegal.com/submit-form/?case_id=43810 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 20, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) a top demand side platform (“DSP”) buyer was shifting a significant number of clients to a new platform which evaluated inventory differently; (2) as a result, PubMatic was seeing a reduction in ad spend and revenue from this top DSP buyer; and (3) as a result of the foregoing, defendants’ positive statements about PubMatic’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the PubMatic class action, go to https://rosenlegal.com/submit-form/?case_id=43810 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Analyst’s Disclosure:I/we have a beneficial long position in the shares of AMZN, NVDA, META, MSFT, GOOGL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK, Sept. 28, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Savara Inc. (“Savara” or “the Company”) (NASDAQ: SVRA) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Savara securities between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/SVRA.

Case Details

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) the MOLBREEVI BLA lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (2) accordingly, the FDA was unlikely to approve the MOLBREEVI BLA in its current form; (3) the foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors; (4) the delay in MOLBREEVI's regulatory approval increased the likelihood that the Company would need to raise additional capital; and (5) as a result, Defendants' public statements were materially false and misleading at all relevant times.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/SVRA. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Savara you have until November 7, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]

NEW YORK, Sept. 28, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Charter Communications, Inc. (“Charter” or “the Company”) (NASDAQ: CHTR) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Charter securities between July 26, 2024 and July 24, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/CHTR.

Case Details

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Charter was not capable of managing the end of the Affordable Connectivity Program (“ACP”); (2) the ACP’s termination resulted in a sustained decline in internet customers and revenue; (3) the Company had no reasonable basis to assert that it was successfully executing its operations plan or effectively managing the causes of customer declines; and (4) as a result, Defendants’ statements about the Company’s business, operations, and prospects were materially false and misleading at all relevant times.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/CHTR. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Charter you have until October 13, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of VONOY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Palantir Technologies (NASDAQ: PLTR) built its reputation on years of base-building before staging an explosive rally, fueled by growing demand for its government and enterprise AI platforms. 

That consolidation phase set the stage for one of the most dramatic moves in recent technology history, with the stock hitting multiple highs in recent months.

As of press time, PLTR shares were trading at $177.57, up 136% year-to-date.

Now, data from charting platform TrendSpider suggests that Snowflake (NYSE: SNOW) may be tracing a similar path. 

While its share price has traded sideways since its IPO, revenue has continued to grow steadily quarter after quarter, mirroring Palantir’s pre-breakout pattern. 

PLTR and SNOW price chart. Source: TrendSpider
With data emerging as the backbone of AI adoption, the parallels raise the question: could Snowflake be the next Palantir?

PLTR and SNOW stock fundamentals 
Palantir’s momentum has been driven by a string of high-profile contracts that expand its dominance in AI-enabled defense and government work. 

The company recently secured a $10 billion U.S. Army contract, signed a major partnership with Boeing’s defense unit, and saw NATO adopt its Maven Smart System, all underscoring its role as a critical AI provider in security and defense.

Snowflake, meanwhile, is broadening its platform beyond data warehousing into full AI infrastructure. The company is acquiring Crunchy Data to strengthen its PostgreSQL and AI app development capabilities, positioning it to compete more directly with Databricks. 

It has also partnered with Salesforce, dbt Labs, and others on the Open Semantic Interchange initiative, aimed at making enterprise data more interoperable for AI applications.

Leadership changes are also underway. In this case, longtime CFO Mike Scarpelli recently stepped down after overseeing a $3 billion share buyback, a move seen as a vote of confidence in Snowflake’s long-term value. 

At the same time, institutional investors have been quietly increasing their stakes, reflecting renewed optimism in the company’s growth trajectory.

Overall, Snowflake’s chart mirrors Palantir’s pre-breakout phase, but while PLTR is already benefiting from major defense contracts, Snowflake is still building its foundation to become an AI-first enterprise platform.

Featured image via Shutterstock

Meta Platforms Today

$743.75 -5.16 (-0.69%)

As of 09/26/2025 04:00 PM Eastern

52-Week Range$479.80▼

$796.25Dividend Yield0.28%

P/E Ratio26.93

Price Target$826.05

Meta Platforms NASDAQ: META recently held one of its biggest events each year: Meta Connect. At this event, the company takes the opportunity to unveil its latest innovations when it comes to consumer devices. This year, Meta released the next generation of its artificial intelligence (AI) glasses: the Meta Ray-Ban Display.

With this device, Mark Zuckerberg may have moved closer to his goal of AI glasses eventually replacing smartphones. However, for investors, what could the Meta Ray-Ban Display mean for the tech stock in the short and long term? Could it be a breakthrough for Meta’s Reality Labs segment? Let’s break down this new device and its potential implications for the stock below.

Get Meta Platforms alerts:

Meta Ray-Ban Display: Huge Advancements, Strong Reviews
Right off the bat, it’s clear that the Meta Ray-Ban Display is a significant upgrade over the company’s past AI glasses. This comes, as the device’s name would suggest; it includes a visual display. Wearers can interact with a two-dimensional display in the right lens. 

Users can now operate the device more discreetly with a visible interface, reducing the need to speak and enabling easier public use.

Wearers can use the display to send and receive messages on WhatsApp, Messenger, and Instagram, and access a map that provides turn-by-turn walking directions. They can also now see a preview of the picture or video they want to capture.

Before, capturing images with the Ray-Ban glasses was somewhat of a guessing game. Meta says this image previewing feature was the number one request it received from users of the previous device. The device can also provide subtitles and translate foreign languages when speaking to another person.

Despite these considerable advancements, the most interesting feature of the device is how wearers interact with the display. With the glasses comes a wristband called the Meta Neural Band.

The band reads electric impulses from the user's arm to detect hand gestures corresponding to different controls. Early reviews of the device have been generally very positive, with Engadget’s Karissa Bell saying it "feels like the beginning of the kind of smart glasses a lot of people have been waiting for."

Strong Adoption Could Alter Investor Outlook on Reality Labs
With this new tech, Meta seems to have taken a big step forward in its mission to one day replace smartphones with AI glasses.

Still, it can’t do nearly as much as a smartphone, and the number of applications users can access is very small. Thus, the Meta Ray-Ban Display doesn’t make the firm any type of real threat to Apple NASDAQ: AAPL at this point. However, the device can add upside to Meta's shares.

Compared to past Meta glasses, the visual display is much more aligned with what smartphones offer. Thus, they provide a tangible and early demonstration of a product that, with further advancements, could compete significantly with smartphones.

Meta Platforms Stock Forecast Today12-Month Stock Price Forecast:
$826.05
11.06% Upside

Moderate Buy
Based on 47 Analyst Ratings

Current Price$743.75High Forecast$980.00Average Forecast$826.05Low Forecast$600.00Meta Platforms Stock Forecast Details

If sales are strong, the prospect of widespread adoption of AI glasses in the future becomes more realistic, as consumers show they are open to this potential future. Seeing this positively shift sentiment on Reality Labs wouldn't be overly surprising.

So far, many have viewed the segment as a nuisance on Meta’s income statement, tolerated due to its impressive advertising business.

The success of the Meta Ray-Ban Display could change this view, positioning Reality Labs as a business with a more verifiable chance of long-term success.

This could create positive near-to-mid-term price action in Meta shares when data on the device’s sales comes out. However, if adoption is weak, an opposite reaction could also occur. Still, Reality Labs has been losing over $3 billion a quarter for at least two years.

Nonetheless, Meta shares have soared over that time, showing that markets aren’t holding this against the company much.

AI Glasses Continue to Add Long-Term Upside Potential
Longer term, the rapid advancement of Meta’s AI glasses continues to support the notion that Meta could one day become a worldwide leader in AI hardware. Its current place as a leader in social media and AI advertising makes it a difficult company to bet against.

Whether its latest device will be a breakthrough for Reality Labs remains in question, but the bullish outlook for the stock continues until something significant changes.

Should You Invest $1,000 in Meta Platforms Right Now?Before you consider Meta Platforms, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Meta Platforms wasn't on the list.

While Meta Platforms currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Creating passive income streams can take many forms. Investors can choose from a plethora of stocks, bonds, alternative assets (such as real estate) and other less-traditional options (including crypto, etc.

Teradyne Today

$135.31 +2.44 (+1.84%)

As of 09/26/2025 04:00 PM Eastern

52-Week Range$65.77▼

$144.16Dividend Yield0.35%

P/E Ratio46.82

Price Target$118.63

A recent jump in Teradyne's NASDAQ: TER stock, which saw it climb over 12% in a single trading session, has caught the market's attention. Such a move is significant for a company with a market capitalization of $21 billion.

It begs the question: Why is a company specializing in semiconductor test equipment suddenly demonstrating such strong momentum?

A closer look reveals this is not a momentary spike but a market awakening to a deeper reality: Teradyne has become an indispensable and foundational player in the artificial intelligence (AI) revolution.

While much of the focus in the AI space is on high-profile chip designers, the success of the entire industry rests on the ability to produce incredibly complex hardware that works flawlessly. This is where Teradyne provides its value.

The company operates as a classic picks and shovels play, supplying the essential tools needed to ensure the gold rush in AI hardware pays off.

The recent stock performance suggests that investors are beginning to fully understand and appreciate the value of the one selling the tools.

Forging the Tools for the AI Era
The primary force behind Teradyne's renewed momentum is AI hardware's explosive growth and complexity. As AI models become more sophisticated, the chips that power them are evolving into technological marvels of unprecedented density and complexity. 

This creates a critical challenge for manufacturers: ensuring quality and yield. The cost of a single defect in a multi-thousand-dollar AI accelerator is enormous, making rigorous testing a crucial quality control step and an economic necessity.

This is where demand for Teradyne's advanced equipment is igniting. On the company's second quarter 2025 earnings call, CEO Greg Smith confirmed this shift, stating that he expects AI compute to be the dominant driver of the core Semiconductor Test business for the rest of the year.

The company is backing this strategy with targeted innovation. Its recently launched Magnum 7H memory tester is a prime example.

This system is purpose-built to handle the unique challenges of testing High Bandwidth Memory (HBM), the ultra-fast memory stacked directly onto high-performance AI GPUs.

With the Magnum 7H already shipping to major HBM manufacturers, Teradyne has a direct line to profit from every new AI server that gets built.

This is further supported by strategic moves, such as the acquisition of Quantifi Photonics, which bolsters its position in testing another critical AI component: silicon photonics.

Where Teradyne’s Strategy Meets the Bottom Line
This strategic positioning in the AI supply chain is already translating into solid financial performance. While second-quarter revenue was down year-over-year, a reflection of residual weakness in consumer and automotive markets, the company's forward guidance signals a powerful, AI-driven rebound is underway.

Key financial metrics highlight this turning point:

Beating Expectations: For Q2 2025, Teradyne reported revenue of $651.8 million and non-GAAP earnings per share (EPS) of $0.57, comfortably surpassing analyst estimates.
Strong Forward Guidance: For Q3 2025, management projects revenue to land between $710 million and $770 million. At the midpoint, this represents a powerful 14% sequential growth rate, giving concrete financial weight to management's optimism.
Profitability and Valuation: The company's non-GAAP operating profit was 15.1% in the second quarter and is projected to expand to 19.5% at the midpoint of Q3 guidance. With a trailing price-to-earnings ratio (P/E) of approximately 46, the stock is valued for its growth potential, which upcoming quarters are forecast to deliver.
Shareholder Returns: This financial strength supports healthy shareholder returns, including a consistent quarterly dividend of $0.12 per share and an active share repurchase program, which removed $119 million of stock from the market in the second quarter alone.

Wall Street's Re-rating Begins
Teradyne Stock Forecast Today12-Month Stock Price Forecast:
$118.63
-12.33% Downside

Moderate Buy
Based on 18 Analyst Ratings

Current Price$135.31High Forecast$200.00Average Forecast$118.63Low Forecast$85.00Teradyne Stock Forecast Details

Following the stock's recent ascent, investors are asking what comes next. A review of Wall Street activity suggests that a reevaluation is in its early stages. According to data from 18 analysts, Teradyne holds a Moderate Buy consensus rating.

While its average price target of $118.63 sits below the current trading price, older targets weigh down this figure.

The most recent analyst revisions, however, show a decidedly bullish trend. For example, Susquehanna recently boosted its price target to $200, citing AI-driven opportunities. This type of revision suggests that some analysts are actively re-rating the stock's potential as the AI growth story becomes clearer.

The breakdown of 11 Buy ratings, 5 Hold ratings, and 2 Sell ratings suggests that positive sentiment is strong, despite the consensus target still falling short of the stock's recent price action.

A Core Holding for the AI Infrastructure Buildout
Teradyne's recent surge is more than just a momentary market reaction; it reflects a fundamental shift in its business. The company's deep-seated expertise in testing complex electronics has placed it at the center of a generation's most significant technological transition.

As the buildout of AI infrastructure continues, the demand for more complex and powerful chips will only grow. With it, the need for the critical testing technology that Teradyne provides will become even more pronounced.

For investors seeking a foundational way to participate in the AI megatrend, Teradyne is moving beyond its cyclical semiconductor identity and emerging as a secular growth story, making it a compelling consideration for any technology-focused portfolio.

Should You Invest $1,000 in Teradyne Right Now?Before you consider Teradyne, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teradyne wasn't on the list.

While Teradyne currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Snap, Inc. ("Snap" or the "Company") (NYSE: SNAP). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Snap and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until October 20, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired  Snap securities during the Class Period. A copy of the Complaint can be obtained a t  www.pomerantzlaw.com .

[Click here for information about joining the class action]

On August 5, 2025, Snap announced its financial results for the second quarter of fiscal year 2025, disclosing a deceleration in advertising revenue growth. The Company attributed the slowdown to "an issue related to our ad platform, the timing of Ramadan, and the effects of the de minimis changes."

On this news, Snap's stock price fell $1.61 per share, or 17.15%, to close at $7.78 per share on August 6, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

          The investigation concerns whether Soleno and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

          On August 15, 2025, Scorpion Capital ("Scorpion") published a report that described Soleno's only product, Vykat XR, as overpriced and potentially unsafe for children. 

          Following publication of the Scorpion report, Soleno's stock price fell $5.73 per share, or 7.41%, to close at $71.63 per share on August 15, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In